You searched for mRNA Therapeutics - Page 4 of 20

In Depth 30 Mar 2020

Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?

The first vaccine against coronavirus disease could one day be made of mRNA. How is mRNA showing promise against the pandemic, and what could it signify for the mRNA field? The global number of coronavirus disease (Covid-19) cases has passed 600,000 and is threatening to bring healthcare systems worldwide to their knees. To control the […]

March 30, 2020 - 7 minutesmins - By Jonathan Smith

News and Trends 8 Nov 2019

EU Project Receives €15M to Bring mRNA Therapy to a Wider Audience

An EU research project has launched with the aim of bringing mRNA treatments to a wider range of patients and diseases. The EXPERT – Expanding Platforms for Efficacious mRNA Therapeutics – project is a collaboration among academics and industry experts from 11 countries who will work on a novel delivery system for messenger (m)RNA therapeutics […]

November 8, 2019 - 4 minutesmins - By External Contributor

biontech cancer vaccine mrna immunotherapy

News and Trends 9 Jul 2019

BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer

In one of the biggest ever funding rounds in European biotech, the German company BioNTech has raised a Series B of €289.5M ($325M) to develop individualized cancer vaccines. BioNTech will use the money to fuel the clinical development of the company’s lead program — an individualized mRNA-based immunotherapy for treating melanoma, which completed a phase […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 1 Mar 2019

Rapid Response mRNA Vaccine Facility Gets €30M Funding

An mRNA vaccine facility, run by the German biotech CureVac, has received a €30M development grant to rapidly manufacture vaccines for regions hit by outbreaks of rabies, yellow fever and emerging diseases. CureVac is a company that develops vaccines made of mRNA, a molecule that lets cells translate genes into proteins. The company’s drug candidates […]

March 1, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 16 Aug 2018

Pfizer Offers €374M for German mRNA Flu Vaccine

BioNTech, based in Mainz, Germany, has entered into a partnership with Pfizer worth up to $425M (€374M) to develop an mRNA-based flu vaccine, which could be produced much more quickly than current flu vaccines. Messenger RNA (mRNA) is one of the building blocks living organisms use to create proteins from genes. BioNTech is developing prophylactic […]

August 16, 2018 - 2 minutesmins - By Alexander Burik

moderna biontech personalized cancer vaccine

News and Trends 15 Nov 2017

US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine

Moderna Therapeutics has started dosing patients with an mRNA-based personalized cancer vaccine that resembles another one being developed by BioNTech. Moderna Therapeutics has announced the start of a Phase 1 study with mRNA-4157, a therapy consisting of a cancer vaccine that is tailored to each patient’s individual tumor. In order to make this personalized treatment, […]

November 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Oct 2017

Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines

CureVac will be working with pharma giant Eli Lilly in the development of up to five cancer vaccines based on mRNA technology. Eli Lilly will pay CureVac $50M (€43M) upfront and invest €45M in equity to kick off a collaboration for the development and commercialization of up to five mRNA vaccines for cancer. CureVac could receive up […]

October 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 19 Sep 2017

RNA as a Therapy: Reviewing the Future Generation of Therapeutics

You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that some believe could be as big a revolution as monoclonal antibodies. For a long time after the discovery of nucleic acids, now almost 150 years […]

September 19, 2017 - 9 minutesmins - By Clara Rodríguez Fernández

Interview 3 Jul 2017

Video: Is mRNA a True Game-Changer? Fireside Chat with Sean Marett, COO of BioNTech

Sean Marett took a red-eye from New York to speak at Refresh last month: here are his thoughts on how mRNA therapeutics are taking biotech by storm! mRNA has become one of the next big things in biotech, and Germany-based BioNTech is at the forefront of the wave, developing personalized treatments for cancer. “We try to provide individualized […]

July 3, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 12 Jun 2017

BioNTech Publishes First Data on mRNA-Encoded Cancer Antibodies

BioNTech has reported a new technology that could overcome some of the most challenging issues of antibody production by encoding them into mRNA drugs. BioNTech, one of the most advanced companies in the mRNA therapeutics field, has reported preclinical data for a new class of mRNA drugs that instruct the body to create its own […]

June 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

mrna astrazeneca cardiometabolic diseases moderna

News and Trends 27 Jul 2016

AstraZeneca plans Phase I trial with mRNA therapy for Cardiovascular Disease

The collaboration between AstraZeneca and the money-magnet Moderna is giving its first steps. AstraZeneca is filing for authorization of a German Phase I trial, to assess an mRNA therapy for cardiometabolic diseases. Therapies using mRNA have a lot of potential as biologics. Leading Biotechs in the field include CureVac (interview with its CCO here) and […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

biontech mrna vaccine cancer immunotherapy nature

News and Trends 2 Jun 2016

First All-Cancer mRNA Vaccine that Works Published in Nature

Update (05/07/2017): BioNTech has published new results in Nature revealing a strong immune response in all 13 patients treated with its personalized mRNA cancer vaccine, strengthening its potential to become a universal cancer vaccine. Originally published on 02/06/2016 BioNTech and its academic partners have published in the well-known publication Nature, describing the first clinically applicable and systemic […]

June 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us